The role of interleukin-11 in acute myeloid leukaemia

The role of interleukin-11 in acute myeloid leukaemia

Project details

Acute myeloid leukaemia (AML) is a cancer that affects the blood and bone marrow, resulting in an overproduction of immature white blood cells. It is an aggressive disease, with current treatments benefiting less than 30 per cent of patients. In order to improve treatment outcomes, it is important to better understand how the disease progresses. We are particularly interested in a cytokine, called interleukin-11 (IL-11), which has previously been linked to AML; however, its function within this disease remains unknown. 

In this project, we will use a number of state-of-the-art imaging and modelling systems together with biochemical and functional analysis of signalling pathways to explore the role of IL-11 in disease progression and treatment. 

 

About our research group

This is a collaborative project, taking advantage of the skills developed by a team of scientists with expertise in leukemia models, clinical leukemia management and the development of biologics for clinical use.  

The Putoczki laboratory is focused on understanding how soluble molecules called cytokines influence the growth and spread of cancer. 

Dr Brumatti is a senior postdoctoral researcher with expertise in investigating new therapies for AML. 

The student and project will benefit from additional collaborations with the Peter MacCallum Institute, Murdoch Children’s Research Institute, and CSL Ltd.

 

 

Researchers:

Dr Tracy Putoczki

Tracy Putoczki
Dr
Tracy
Putoczki
Laboratory Head
Gabriela Brumatti profile photo
Dr
Gabriela
Brumatti
Cell Signalling and Cell Death division

Project Type: